trial · primary record
CMVpp65-A*0201 peptide vaccine
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 61 |
| Primary completion | 2024-09-19 |
| Primary endpoint | Cumulative Incidence of CMV at 100 Days |
| Registry ID | NCT02396134 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:58.768Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02396134
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.